Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Use of Everolimus and Trastuzumab in Addition to Endocrine Therapy in Hormone-Refractory Metastatic Breast Cancer

Published:2019-06 Issue:3 Volume:19 Page:188-196
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Paplomata Elisavet,Zelnak Amelia,Santa-Maria Cesar A.,Liu Yuan,Gogineni Keerthi,Li Xiaoxian,Moreno Carlos S.,Chen Zhengjia,Kaklamani Virginia,O’Regan Ruth M.

Funder

Pfizer

MedImmune

Novartis

Eisai

Genentech

Corcept Therapeutics

Seattle Genetics

Abbvie

Merck

Hoosier Research Cancer Network

NIH

NCI

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference36 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

2. Enhancing endocrine therapy for hormone receptor-positive advanced breast cancer: cotargeting signaling pathways;Johnston;J Natl Cancer Inst,2015

3. Endocrine resistance in breast cancer–an overview and update;Clarke;Mol Cell Endocrinol,2015

4. Emerging targeted agents in metastatic breast cancer;Zardavas;Nat Rev Clin Oncol,2013

5. New strategies in estrogen receptor-positive breast cancer;Johnston;Clin Cancer Res,2010

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer;Clinical Breast Cancer;2020-04

2. Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics;Cancer Drug Resistance;2019